Wan‐Long Chuang

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update

Yun‐Fan Liaw, Jia‐Horng Kao, Teerha Piratvisuth et al. · Hepatology International · 2012 · 1K citations

Medicine, Internal Medicine, Hepatology +11

Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial

Edward Gane, Wai Kay Seto, Henry Lik‐Yuen Chan et al. · ˜The œLancet. Gastroenterology & hepatology · 2016 · 546 citations

Pharmacy, Infectious Diseases, Pharmacology +12

Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial

Henry Lik‐Yuen Chan, Scott Fung, Wai Kay Seto et al. · ˜The œLancet. Gastroenterology & hepatology · 2016 · 458 citations

Pharmacy, Infectious Diseases, Pharmacology +11

Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

Stefan Zeuzem, Graham R. Foster, Stanley Wang et al. · New England Journal of Medicine · 2018 · 437 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection

Kosh Agarwal, Maurizia Rossana Brunetto, Wai Kay Seto et al. · Journal of Hepatology · 2018 · 423 citations · Full text

Pharmacy, Infectious Diseases, Pharmacology +10